Certis Biologicals Expands International Personnel to Answer Rising Global Demand
11.8.2021 15:17:00 CEST | Business Wire | Press Release
To meet the rising demand for biological-based crop protection products, Certis Biologicals today announced new additions to its headquarters team. Tarang Srivastava begins immediately as Head of International Business, responsible for business strategy and financial objectives in international markets and working with distribution partners, external business partners and internal teams to expand biologicals globally. Srivastava’s focus will lay in providing solutions to growers in European markets. Srivastava formally worked on Bharat Certis Insecticide Limited for parent company Mitsui & Co. and brings extensive experience in establishing global positions to the new role.
Additionally, Certis Biologicals welcomes Moto Mitani to the International Business Team. Mitani will lead the Certis teams for Asia and Africa as well as supporting Certis Biologicals’ Specialty Chemical Sales division. Mitani joins from Mitsui AgriScience where he served as Business Manager responsible for international sales.
Amanda Eade joins the Global Marketing Team as Global Portfolio Manager for Bioinsecticides and Bioherbicides, assessing market capacity for Certis’ proven portfolio of bio-based insecticide and herbicide solutions, including Bt portfolio products, Firefighter©, Requiem Prime© and Homeplate©. Eade brings extensive experience from posts with Open Book Extracts as Operations Manager, BASF as portfolio manager and Dow Agrisciences as sales representative.
“Currently, Certis Biologicals distributes bio-based solutions in more than 50 countries worldwide and we see a growing need in areas where synthetic chemistries are growing scarce and regulations are high,” says Amy O’Shea, President and CEO. “We want to ensure that every grower, no matter where they are located, has access to our portfolio and we believe these additions to our staff will be key to achieving that goal.”
The additions of Srivastava, Mitani and Eade come in the wake of Certis Biologicals’ announcement that Rob Gibson joined as Global Product Manager and Ryutaro Matsuhashi, VP of International Business, had expanded his role within the biologicals leader to focus on growth in Latin America. In that capacity, Matsuhashi has seen success in expanding the company’s portfolio in Brazil.
“We are proud to be headquartered in the U.S., but Certis Biologicals is a true global distributor of biologicals,” says O’Shea. “We are investing in the talent and expertise needed to ensure that we can be the full-line provider of biologicals to all growers and distributors.”
Currently, Certis Biologicals innovates across six technology platforms, including bacteria-based technologies, fungi-based products, virus technologies, bacteriophage technologies, biochemicals and need-seed extracts. The company distributes nearly 40 integrated biological crop protection solutions to growers in more than 50 countries. Certis’ robust research and development pipeline is planning numerous new products and formulations coming to market over the next 3-5 years.
Growers and distributors who are interested in Certis Biologicals can visit www.CertisBio.com to learn more about the company’s portfolio of bio-solutions for organic and conventional farming.
About Certis Biologicals
Certis Biologicals is the leading manufacturer, innovator, developer and marketer of proven biological solutions for use in commercial agriculture and the garden and greenhouse markets.
With biological products sold through a global distribution network and in collaboration with various technology, regulatory and sourcing companies in more than 50 countries, Certis Biologicals meets the challenges faced by today’s growers around the globe to feed a growing population while sustaining the natural resources and environments necessary for a healthy planet.
To learn more about Certis Biologicals, their portfolio of proven solutions, or their commitment to sustainability, visit www.CertisBio.com or follow the company through social media on Facebook, Twitter, LinkedIn and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005074/en/
Contact information
Jamie Sears Rawlings
502-931-5004
Jamie@runswitchpr.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom